Health challenges need predictable healthcare investment policies. Japan’s example shows why

(Credit: Unsplash)

This article is brought to you thanks to the collaboration of The European Sting with the World Economic Forum.

Author: Joseph Damond, Deputy Chief Policy Officer & Executive Vice President, International Affairs, Biotechnology Innovation Organization


  • Japan’s government is building partnerships with the biopharma sector on COVID vaccines.
  • Though it does not have a home-grown COVID vaccine, Japanese society now benefits from the global industry’s ability to successfully turn years of research and investment in platform technologies such as mRNA into life-saving products to fight the pandemic.
  • But there is more that Japan could do to work together with the global biotech and life sciences sector to become a world leader – offering lessons for other countries.

Japan has a world-class technological base but without a predictable and welcoming policy environment for the biopharma sector to thrive, it falls short of becoming a biotech and life sciences world leader.

The limitations in competitiveness of its biopharmaceutical sector are highlighted by its lack of a home-grown COVID vaccine, due in large part to a policy environment that is sending the wrong signals to those who would invest in developing innovative medicines in Japan.

For example, Japan has made 56 changes to pharmaceutical pricing rules in recent years, creating significant uncertainty for local and international biotech companies. These changes have become increasingly abrupt and non-transparent, with limited prior notification or opportunities for public comment.

The implementation of multiple, overlapping rules has created a volatile market in which companies are repeatedly blindsided by major revisions in supply terms. This is part of a concerning trend by a number of governments to impose onerous requirements on health suppliers. Other examples include Canada’s revisions of its Patented Medicines Prices Review Board guidelines and the Republic of Korea’s opaque reimbursement practices.

While the Japanese government faces the challenge of sustaining its healthcare system in the face of both the COVID crisis and an ageing population, it has unusually singled out medicines as its primary target for what it sees as healthcare “savings.” 75% of cost savings delivered within the social security system are sourced from pharmaceuticals, even though they make up only about 20% of Japanese healthcare spending. Whatever the short-term fiscal benefits of this strategy, it has a chilling effect on Japan’s long-term investment climate in the risky and expensive biotechnology and life sciences space.

US-sourced Foreign Direct Investment (FDI) into Japan grew at only 16% between 2010 and 2019, whereas China saw growth of 97% and Singapore 180% over the same period, and Japan has the lowest inbound FDI stocks as a share of GDP in the OECD. Business investment in pharmaceutical R&D has fallen by an annual rate of 1% in Japan since 2013.

Business enterprise investment in pharmaceutical R&D. Image: EIU

Any decision to increase investment in pharmaceutical research, clinical development or commercial capabilities in Japan would be closely scrutinized under current circumstances. The alternative is that Japan could fall further behind its neighbours in the global life sciences race.

Japan’s uncertain policy environment also undermines efforts to drive healthcare innovation to serve patients. A little over a decade ago, the government of Japan made great progress in improving the regulatory environment for new medicines. It successfully eliminated the “drug lag” that had prevented Japanese patients from accessing valuable medicines until many years after patients in the US and Europe.

The current volatility in Japan’s policy environment puts this progress at risk as new medicines and indications may only become available after being launched in more stable markets. The existing pipeline of new medicines in development is dominated by new technologies: not only advanced biologics, but gene and cell therapies. Japan’s current healthcare system struggles to value the benefits of these drugs and get them to Japanese patients after they are approved by its regulatory agency, the PMDA.

Japan’s increasing adoption of non-transparent cost-containment measures has other global consequences too. As every government is trying to build back better after COVID while simultaneously preparing for future threats, finding solutions for current and future health challenges will require an ever expanding portfolio of new medicines and vaccines that will take time and money to discover and develop. healthcare

What is the World Economic Forum doing about healthcare value and spending?

Each year, $3.2 trillion is spent on global healthcare making little or no impact on good health outcomes.

To address this issue, the World Economic Forum created the Global Coalition for Value in Healthcare to accelerate value-based health systems transformation.

This council partners with governments, leading companies, academia, and experts from around the world to co-design and pilot innovative new approaches to person-centered healthcare.

For example, the mRNA platform technology is a result of years of research as well as long-term, highly uncertain investment in the global biopharma ecosystem, which has led to life-saving products to fight today’s COVID crisis. But first Japan will need to balance its fiscal pressures more equitably across the healthcare sector, address the real inefficiencies in its healthcare delivery system, and promote its innovative life sciences sector all at the same time. Japan certainly has the means, and it has much of the technology to achieve this.

A good first step would be to bring all stakeholders together to discuss the best ways to achieve better healthcare while supporting a vibrant ecosystem for biotechnology research. This should include valuation and reimbursement processes that provide strong incentives for innovation, especially the most advanced technologies.

Any subsequent processes to implement reforms should be transparent and consultative. As the US and Japan strive to deepen cooperation in research and technology development in biotechnology, as announced in the recent US-Japan Joint Leaders’ Statement, our industry will continue to work collaboratively to create the conditions needed to deliver the best possible outcomes for patients and communities in Japan and globally.

BIO is working on a report to propose how Japan could do more to promote public health and become a leader in the innovative global life sciences sector.

the sting Milestones

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

MasterCard at European Business Summit 2015: A focus on innovation will drive inclusive economic growth for Europe

Children are still dying in Yemen war, despite partial ceasefire, says UNICEF chief

London wants new skyscrapers to protect cyclists from wind tunnels

Security Union: Commission receives mandate to start negotiating international rules for obtaining electronic evidence

Release of prize-winning Reuters journalists in Myanmar welcomed by UN

The EU’s outermost regions: strengthened partnership bears fruit

EU prolongs economic sanctions on Russia by six months

European Citizens’ Initiative: Commission decides to register ‘Right to Cure’ initiative

10 lessons from the COVID-19 frontline for a more gender-equal world

The European Parliament rewrites the EU budget in a bright day for the Union

Why exchange programs are essential for the medical students of the 21st century

Doctors vs. Industry 4.0: who will win?

Western Balkans: MEPs take stock of 2018 progress

World Health Organization calls crisis meeting over deadly Ebola outbreak in DR Congo

Business uncertainty rises as US grants only temporary exception to EU for steel and aluminium tariffs

Cybersecurity needs a holistic approach. Here are three ways to build protection

Commission offers discount on fines to banks for competition infringements

Oleg Sentsov awarded the 2018 Sakharov Prize

These 5 charts show our shifting behaviour around coronavirus

Conflict, climate change among factors that increase ‘desperation that enables human trafficking to flourish’, says UN chief

Nine children killed or maimed in Afghanistan every day: UN Children’s Fund

Although Greece is struggling to pay salaries and pensions Varoufakis is “optimistic”; the Sting reports live from EBS 2015

Draghi repels Trump’s threats, rejects Schauble’s dictums

This surgeon runs a makeshift hospital for over 200,000 people

UN chief extends condolences to families of China landslide casualties

Education in Emergencies: EU announces record humanitarian funding for 2019 and launches #RaiseYourPencil Campaign

A European Discovers China: 3 First Impressions

Why philanthropy for – and by – Africans is the future

Voices of Afghan women ‘must be heard at the table in the peace process and beyond’ UN deputy chief tells Security Council

Drinking water: new plans to improve tap water quality and cut plastic litter

JADE Team at the European Business Summit 2017

Respect people’s peaceful assembly and fair trail rights, UN human rights wing urges Nicaragua

The consequences of Brexit seen by a European young entrepreneur

The EU Spring Summit set to challenge austerity

How India is solving its cooling challenge

Why the 21st century’s biggest health challenge is our shared responsibility

These entrepreneurs are turning discarded fishing nets into surfboards and swimwear

Building cybersecurity capacity through benchmarking: the Global Cybersecurity Index

Ministers for Youth miss the opportunity to improve social inclusion of young people

Harnessing the power of nature in the fight against climate change

Nearly three million more displaced year-on-year, warns refugee agency chief, but solutions are within reach

UN commission agrees roadmap on ensuring women’s social protection, mobility, safety, and access to economic opportunities

EU confronts environmental threats as global leaders attempt to revive the global sentiment at NYC climate week

Why remote working doesn’t have to mean alienated employees

UN chief seeking ‘renewed commitment’ to global rules and values, as world leaders head to New York

Strong multilateral institutions key to tackling world’s dramatic challenges, UN chief says In Moscow

We had the hottest June ever this year – this is what happened around the world

Human Rights and Democracy: striving for dignity and equality around the world

China, forever new adventures

Employment and Social Developments in Europe: 2018 review confirms positive trends but highlights challenges, in particular linked to automation and digitalisation

Main results of Asia-Europe Meeting (ASEM) – 18-19/10/2018

UN expert condemns new sentence for jailed Venezuelan judge as ‘another instance of reprisal’

This new programme could hold the key to solving global health challenges

Two-thirds of employees would trust a robot boss more than a real one

LGBTQ+ inclusion on the other side of the screen

How communities are dealing with economy, society and education in COVID-19 crisis     

A Sting Exclusive: EU Commission’s Vice President Šefčovič accentuates the importance of innovation to EU’s Energy Union

November infringements package: key decisions

Bigotry makes politicians ‘complicit in the violence that follows’ : UN independent experts

Acute food insecurity ‘far too high’ UN agency warns, as 113 million go hungry

More Stings?

Trackbacks

  1. […] Read More: Health challenges need predictable healthcare investment policies. Japan’s […]

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s